トリフルペリドール
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/10/07 03:57:15」(JST)
[Wiki en表示]
Trifluperidol
|
| Clinical data |
| AHFS/Drugs.com |
International Drug Names |
Routes of
administration |
Oral |
| ATC code |
|
| Identifiers |
IUPAC name
- 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one
|
| CAS Number |
|
| PubChem CID |
|
| ChemSpider |
|
| UNII |
|
| ChEMBL |
|
| ECHA InfoCard |
100.016.519 |
| Chemical and physical data |
| Formula |
C22H23F4NO2 |
| Molar mass |
409.417 g/mol |
| 3D model (JSmol) |
|
SMILES
-
FC(F)(F)c1cccc(c1)C3(O)CCN(CCCC(=O)c2ccc(F)cc2)CC3
|
InChI
-
InChI=1S/C22H23F4NO2/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26/h1,3-4,6-9,15,29H,2,5,10-14H2 Y
-
Key:GPMXUUPHFNMNDH-UHFFFAOYSA-N Y
|
| NY (what is this?) (verify) |
Trifluperidol is a typical antipsychotic of the butyrophenone chemical class. It has general properties similar to those of haloperidol, but is considerably more potent by weight, and causes relatively more severe side effects, especially tardive dyskinesia and other extrapyramidal effects. It is used in the treatment of psychoses including mania and schizophrenia. It was discovered at Janssen Pharmaceutica in 1959.
Synthesis
Trifluperidol Synthesis: P. Janssen, J. Adriaan,
GB 895309 (1962),
U.S. Patent 3,438,991 (1969).
References
- Gallant DM, Bishop MP, Timmons E, Steele CA, A controlled evaluation of Trifluperidol: a new potent psychopharmacologic agent, Curr Ther Res Clin Exp. 1963 Sep;27:463-71.
- Gallant DM, Bishop MP, Timmons E, Steele CA, Trifluperidol: a butyrophenone derivative, Am J Psychiatry. 1963 Nov;120:485-7.
|
Antipsychotics (N05A)
|
| Typical |
- Butyrophenones: Benperidol
- Bromperidol
- Droperidol
- Haloperidol#
- Moperone
- Pipamperone
- Spiperone
- Timiperone
- Trifluperidol
- Diphenylbutylpiperidines: Fluspirilene
- Penfluridol
- Pimozide
- Phenothiazines: Acetophenazine
- Butaperazine
- Carphenazine (carfenazine)‡
- Chlorpromazine
- Cyamemazine
- Dixyrazine
- Fluphenazine
- Levomepromazine (methotrimeprazine)
- Mesoridazine
- Perazine
- Periciazine
- Perphenazine
- Piperacetazine
- Pipotiazine
- Prochlorperazine
- Promazine
- Sulforidazine
- Thiopropazate
- Thioproperazine
- Thioridazine
- Trifluoperazine
- Triflupromazine
- Thioxanthenes: Chlorprothixene
- Clopenthixol
- Flupentixol
- Tiotixene (thiothixene)
- Zuclopenthixol
|
| Disputed |
- Benzamides: Amisulpride
- Levosulpiride
- Nemonapride
- Remoxipride‡
- Sulpiride
- Sultopride
- Tiapride
- Veralipride‡
- Butyrophenones: Melperone
- Tricyclics: Carpipramine
- Clocapramine
- Clorotepine
- Clotiapine
- Loxapine
- Mosapramine
|
| Atypical |
- Benzisoxazole/benzisothiazoles: Iloperidone
- Lurasidone
- Paliperidone
- Paliperidone palmitate
- Perospirone
- Risperidone#
- Ziprasidone
- Butyrophenones: Lumateperone†
- Phenylpiperazines/quinolinones: Aripiprazole
- Aripiprazole lauroxil
- Brexpiprazole
- Cariprazine
- RP-5063†
- Tricyclics: Asenapine
- Clozapine#
- Olanzapine
- Quetiapine
- Zotepine
- Others: Blonanserin
- Pimavanserin
- Sertindole
|
| Others |
- Azacyclonol
- Cannabidiol
- Oxypertine
- Reserpine
- Tetrabenazine
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
Dopamine receptor modulators
|
| D1-like |
| Agonists |
- Benzazepines: 6-Br-APB
- Fenoldopam
- SKF-38,393
- SKF-77,434
- SKF-81,297
- SKF-82,958
- SKF-83,959
- Trepipam
- Zelandopam
- Ergolines: Cabergoline
- CY-208,243
- Dihydroergocryptine
- LEK-8829
- Lisuride
- Pergolide
- Terguride
- Dihydrexidine derivatives: A-77636
- A-86929
- Adrogolide (ABT-431, DAS-431)
- Dihydrexidine
- Dinapsoline
- Dinoxyline
- Doxanthrine
- Phenethylamines: BCO-001
- Deoxyepinephrine (N-methyldopamine, epinine)
- Dopexamine
- Etilevodopa
- Ibopamine
- L-DOPA (levodopa)
- Melevodopa
- L-Phenylalanine
- L-Tyrosine
- XP21279
- Others: A-68930
- Apomorphine
- Isocorypalmine
- Nuciferine
- PF-6649751
- PF 6669571
- Propylnorapomorphine
- Rotigotine
- SKF-89,145
- SKF-89,626
- Stepholidine
- Tetrahydropalmatine
|
| Antagonists |
- Typical antipsychotics: Butaclamol
- Chlorpromazine
- Chlorprothixene
- Flupentixol (flupenthixol) (+melitracen)
- Fluphenazine
- Loxapine
- Perphenazine (+amitriptyline)
- Pifluthixol
- Thioridazine
- Thiothixene
- Trifluoperazine (+tranylcypromine)
- Zuclopenthixol
- Atypical antipsychotics: Asenapine
- Clorotepine
- Clotiapine
- Clozapine
- DHA-clozapine
- Fluperlapine
- Iloperidone
- Norclozapine
- Norquetiapine
- Olanzapine (++fluoxetine)
- Paliperidone
- Quetiapine
- Risperidone
- Tefludazine
- Zicronapine
- Ziprasidone
- Zotepine
- Others: Berupipam
- Ecopipam
- EEDQ
- Metitepine (methiothepin)
- Odapipam
- Perlapine
- SCH-23390
|
|
| D2-like |
| Agonists |
- Adamantanes: Amantadine
- Memantine
- Rimantadine
- Aminotetralins: 5-OH-DPAT
- 7-OH-DPAT
- 8-OH-PBZI
- Rotigotine
- UH-232
- Ergolines: Bromocriptine
- Cabergoline
- Dihydroergocryptine
- Epicriptine
- Lisuride
- LSD
- Pergolide
- Terguride
- Dihydrexidine derivatives: 2-OH-NPA
- Ciladopa
- Dihydrexidine
- Dinoxyline
- N,N-Propyldihydrexidine
- Phenethylamines: Deoxyepinephrine (N-methyldopamine, epinine)
- Dopexamine
- Etilevodopa
- Ibopamine
- L-DOPA (levodopa)
- L-Phenylalanine
- L-Tyrosine
- Melevodopa
- XP21279
- Atypical antipsychotics: Alentemol (U-66444B)
- Aripiprazole (+sertraline)
- Aripiprazole lauroxil
- Bifeprunox
- Brexpiprazole
- Cariprazine
- F-15063
- Lumateperone
- Norclozapine
- RP5063
- Others: 3-PPP
- A-412,997
- ABT-670
- ABT-724
- Adrafinil
- Aplindore
- Apomorphine
- Arketamine
- Armodafinil
- BP-897
- Captodiame
- CP-226,269
- Dizocilpine
- Esketamine
- Flibanserin
- GSK-789,472
- Ketamine
- Mesulergine
- Modafinil
- OSU-6162
- Pardoprunox
- PD-128,907
- PD-168,077
- PF-219,061
- PF-592,379
- Phencyclidine
- Piribedil
- Pramipexole
- Preclamol
- Propylnorapomorphine
- Pukateine
- Quinagolide
- Quinelorane
- Quinpirole
- RDS-127
- Ro10-5824
- Ropinirole
- Roxindole
- Salvinorin A
- SKF-83,959
- Sumanirole
- Talipexole
- Umespirone
- WAY-100,635
|
| Antagonists |
|
|
- See also: Receptor/signaling modulators
- Adrenergics
- Serotonergics
- Monoamine reuptake inhibitors
- Monoamine releasing agents
- Monoamine metabolism modulators
- Monoamine neurotoxins
|
English Journal
- Antifungal application of nonantifungal drugs.
- Stylianou M1, Kulesskiy E, Lopes JP, Granlund M, Wennerberg K, Urban CF.
- Antimicrobial agents and chemotherapy.Antimicrob Agents Chemother.2014;58(2):1055-62. doi: 10.1128/AAC.01087-13. Epub 2013 Nov 25.
- Candida species are the cause of 60% of all mycoses in immunosuppressed individuals, leading to ∼150,000 deaths annually due to systemic infections, whereas the current antifungal therapies either have toxic side effects or are insufficiently efficient. We performed a screening of two compound lib
- PMID 24277040
- Re-evaluation of in vivo selectivity of [(11)C]SA4503 to σ(1) receptors in the brain: contributions of emopamil binding protein.
- Toyohara J1, Sakata M, Ishiwata K.
- Nuclear medicine and biology.Nucl Med Biol.2012 Oct;39(7):1049-52. doi: 10.1016/j.nucmedbio.2012.03.002. Epub 2012 Apr 10.
- INTRODUCTION: Carbon-11-labeled 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine ([(11)C]SA4503) was shown to be a promising PET ligand for mapping σ(1) receptors, and was applied to human subjects. However, an in vitro study indicated that SA4503 also binds to the emopamil binding pro
- PMID 22497960
- International consensus study of antipsychotic dosing.
- Gardner DM1, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ.
- The American journal of psychiatry.Am J Psychiatry.2010 Jun;167(6):686-93. doi: 10.1176/appi.ajp.2009.09060802. Epub 2010 Apr 1.
- OBJECTIVE: Potency equivalents for anti-psychotic drugs are required to guide clinical dosing and for designing and interpreting research studies. Available dosing guidelines are limited by the methods and data from which they were generated.METHOD: With a two-step Delphi method, the authors surveye
- PMID 20360319
Japanese Journal
- Determination of clocapramine and its metabolites in plasma by automated column-switching high performance liquid chromatography.
- HIKIDA Kozo,INOUE Yoshimasa,KOJIMA Norio,OHKURA Yosuke
- Analytical Sciences 6(3), 367-370, 1990
- … The drug and the metabolites were extracted together with trifluperidol as an internal standard with a heptane-chloroform mixture from plasma. …
- NAID 130003528974
- EFFECTS OF NEUROLEPTIC BUTYROPHENONES ON PITUITARYADRENAL ACTIVITY IN RATS
- AIMOTO TACHIO,KAIDA MORIO,SATO MASAHIKO,SATO MASAKI,KIMURA RYOHEI,MURATA TOSHIRO
- Journal of pharmacobio-dynamics 3(1), 46-52, 1980-01
- … The effects of some neuroleptic butyrophenones such as haloperidol, clofluperol, trifluperidol, lenperone, moperone, and floropipamide on pituitary-adrenal activity were studied in rats following a single i.p. … The actions of haloperidol, clofluperol, and trifluperidol were shown to be most potent, while floropipamide was the weakest among them. …
- NAID 110003635780
- Effects of neuroleptic butyrophenones on pituitary-adrenal activity in rats.
- AIMOTO TACHIO,KAIDA MORIO,SATO MASAHIKO,SATO MASAKI,KIMURA RYOHEI,MURATA TOSHIRO
- Journal of Pharmacobio-Dynamics 3(1), 46-52, 1980
- … The effects of some neuroleptic butyrophenones such as haloperidol, clofluperol, trifluperidol, lenperone, moperone, and floropipamide on pituitary-adrenal activity were studied in rats following a single i.p. … The actions of haloperidol, clofluperol, and trifluperidol were shown to be most potent, while floropipamide was the weakest among them. …
- NAID 130003544313
Related Links
- Trifluperidolとは？goo Wikipedia (ウィキペディア) 。出典：Wikipedia（ウィキペディア）フリー百科事典。 Trifluperidolとは - goo Wikipedia (ウィキペディア) gooトップ サイトマップ スタートページに設定 RSS ヘルプ メニューへスキップ 本文へ ...
- Trifluperidol Classification: BAN (British Approved Name), USAN (United States Accepted Name), rINN (Recommended International Nonproprietary Name / Generic Name) ... Drugs.com Mobile Apps The easiest way to lookup drug ...
Related Pictures
